Atika Capital Management’s Neurocrine Biosciences NBIX Stock Holding History

Atika Capital Management’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-48,000	Closed	-$6.55M	–	87
2024 Q4	$6.55M	Buy	+48,000	New	+$5.94M	0.7%	46
2024 Q3	–	Sell	-44,500	Closed	-$6.13M	–	105
2024 Q2	$6.13M	Sell	44,500 -13,500	-23%	-$1.85M	0.6%	55
2024 Q1	$8M	Buy	58,000 +8,000	+16%	+$1.09M	0.79%	47
2023 Q4	$6.59M	Sell	50,000 -4,000	-7%	-$460K	0.88%	47
2023 Q3	$6.08M	Buy	+54,000	New	+$5.69M	0.8%	49
2020 Q1	–	Sell	-45,000	Closed	-$4.84M	–	97
2019 Q4	$4.84M	Sell	45,000 -12,000	-21%	-$1.26M	0.93%	51
2019 Q3	$5.14M	Sell	57,000 -8,000	-12%	-$747K	1.08%	41
2019 Q2	$5.49M	Buy	+65,000	New	+$5.34M	1.08%	38
2016 Q1	–	Sell	-50,000	Closed	-$2.83M	–	54
2015 Q4	$2.83M	Sell	50,000 -23,500	-32%	-$1.19M	1.46%	26
2015 Q3	$2.92M	Buy	73,500 +1,150	+2%	+$55.6K	1.43%	28
2015 Q2	$3.46M	Buy	72,350 +21,150	+41%	+$897K	1.56%	23
2015 Q1	$2.03M	Buy	51,200 +36,200	+241%	+$1.29M	1.36%	34
2014 Q4	$335K	Buy	+15,000	New	+$284K	0.24%	64

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Atika Capital Management's NBIX Position: Q1 2025 in Review

Atika Capital Management sold out of Neurocrine Biosciences (NBIX) in Q1 2025, closing a stake of 48,000 shares — an estimated $6.55M sold.

Atika Capital Management first reported a position in NBIX in Q4 2014 and held it in 13 quarters. The position peaked at $8M in Q1 2024. 586 funds tracked by Wall St. Rank hold NBIX as of Q1 2025.

Atika Capital Management reported no remaining Neurocrine Biosciences position as of Q1 2025 after selling out during the quarter.
Atika Capital Management sold 48,000 Neurocrine Biosciences shares in Q1 2025, an estimated $6.55M.
Atika Capital Management first reported a position in Neurocrine Biosciences in Q4 2014 and held it in 13 quarters.
Atika Capital Management's Neurocrine Biosciences position peaked at $8M in Q1 2024.
586 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2025.

Based on Atika Capital Management's 13F filing for Q1 2025, filed 14 May 2025.